GlassScriptPhysician profile
Lori Michelle Kautzman
NPI 1962555888
$6,532.42
in general payments reported to CMS, 2019-2025
20 companies · $542 in 2025
The $542 reported for 2025 was more than what a typical Transplant Surgery provider received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.68 · 2021: $4,077 · 2022: $379 · 2023: $924 · 2024: $595 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,621 · Travel and Lodging: $439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,621.23 |
| Travel and Lodging | $439.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,763.16 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $832.79 | 2020-2025 | Xifaxan |
| Transmedics, INC. | $439.00 | 2023 | Organ Care System |
| Xvivo Perfusion INC. | $332.00 | 2025 | Xvivo Perfusion System (Xps) |
| Intercept Pharmaceuticals, INC. | $308.45 | 2021-2024 | Ocaliva |
| Haemonetics Corporation | $135.29 | 2024 | Teg6s Hemostasis System |
| Eisai INC. | $113.28 | 2022-2025 | |
| Abbvie INC. | $104.43 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.22 | 2023-2025 | Livtencity |
| Hemosonics LLC | $65.82 | 2023 | Quantra Qplus System |
| Merck Sharp & Dohme LLC | $63.86 | 2023-2024 | Prevymis, Dificid |
| Dynavax Technologies Corporation | $55.99 | 2022-2023 | Heplisav-B |
| Vbi Vaccine (Delaware) INC. | $52.29 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $42.45 | 2024-2025 | Iqirvo, Bylvay |
| Laborie Medical Technologies Corp. | $37.68 | 2024 | Renovarp |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $24.69 | 2025 | Rezdiffra |
| Alnylam Pharmaceuticals INC. | $23.46 | 2023 | Oxlumo |
| Novo Nordisk INC | $17.28 | 2025 | Wegovy |
| Eton Pharmaceuticals, INC. | $16.82 | 2025 | Betaine Anhydrous, Nitisinone, Galzin |
| Ethicon US, LLC | $13.46 | 2023 | Neuwave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Kautzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.